scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Acquired by Mitsubishi UFJ Asset Management Co. Ltd.

Mitsubishi UFJ Asset Management Co. Ltd. increased its position in shares of scPharmaceuticals Inc. (NASDAQ:SCPH) by 31.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 23,471 shares of the company’s stock after acquiring an additional 5,633 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in scPharmaceuticals were worth $84,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. BNP Paribas Financial Markets lifted its position in shares of scPharmaceuticals by 116.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 5,753 shares of the company’s stock valued at $26,000 after acquiring an additional 3,101 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of scPharmaceuticals during the third quarter valued at $46,000. Legato Capital Management LLC acquired a new position in shares of scPharmaceuticals in the 4th quarter valued at $37,000. China Universal Asset Management Co. Ltd. purchased a new position in scPharmaceuticals in the 4th quarter worth about $38,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in scPharmaceuticals during the 3rd quarter worth about $57,000. 89.52% of the stock is currently owned by institutional investors.

scPharmaceuticals Price Performance

NASDAQ SCPH opened at $2.32 on Friday. The company has a debt-to-equity ratio of 1.66, a current ratio of 8.08 and a quick ratio of 6.89. The firm has a market capitalization of $116.66 million, a price-to-earnings ratio of -1.22 and a beta of 0.38. The company has a 50 day simple moving average of $3.15 and a 200-day simple moving average of $3.61. scPharmaceuticals Inc. has a 52-week low of $2.20 and a 52-week high of $5.65.

scPharmaceuticals (NASDAQ:SCPH) last released its earnings results on Wednesday, March 19th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.05. scPharmaceuticals had a negative net margin of 264.60% and a negative return on equity of 244.93%. The company had revenue of $12.15 million during the quarter, compared to the consensus estimate of $12.08 million. Equities research analysts predict that scPharmaceuticals Inc. will post -1.53 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

SCPH has been the subject of several recent analyst reports. Maxim Group decreased their target price on shares of scPharmaceuticals from $20.00 to $12.00 and set a “buy” rating for the company in a report on Thursday, March 20th. HC Wainwright reiterated a “buy” rating and set a $18.00 price objective on shares of scPharmaceuticals in a research report on Thursday, March 20th.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.